Last reviewed · How we verify

ND0612 — Competitive Intelligence Brief

ND0612 (ND0612) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor (levodopa) combination therapy. Area: Neurology.

phase 3 Dopamine precursor (levodopa) combination therapy Dopamine pathway; levodopa is converted to dopamine via aromatic amino acid decarboxylase Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ND0612 (ND0612) — NeuroDerm Ltd.. ND0612 is a subcutaneous infusion formulation of levodopa/carbidopa that continuously delivers dopamine precursor to the brain to treat motor symptoms of Parkinson's disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ND0612 TARGET ND0612 NeuroDerm Ltd. phase 3 Dopamine precursor (levodopa) combination therapy Dopamine pathway; levodopa is converted to dopamine via aromatic amino acid decarboxylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor (levodopa) combination therapy class)

  1. NeuroDerm Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ND0612 — Competitive Intelligence Brief. https://druglandscape.com/ci/nd0612. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: